{
    "nct_id": "NCT03873402",
    "official_title": "A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors",
    "inclusion_criteria": "* Histological confirmation of renal carcinoma with clear cell component including participants who may have sarcomatoid features.\n* Advanced (not amenable to curative surgery or radiation therapy) renal cell carcinoma (RCC) or metastatic RCC (mRCC).\n* Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria.\n* No prior systemic therapy for RCC\n* Must be intermediate or poor risk as per International Metastatic RCC Database Consortium (IMDC).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any active central nervous system (CNS) metastases.\n* Active, known, or suspected autoimmune disease.\n* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody, or any other agents specifically targeting T-cell co-stimulation or checkpoint pathways\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}